Feasibility 'innate' allogeneic stem cells transplantio
- Conditions
- Hematological malignancies (hematologische maligniteiten)Allogeneic stem cells transplantation (allogene stamcel transplantatie)Innate immune system (aangeboren immuunsysteem)
- Registration Number
- NL-OMON25484
- Lead Sponsor
- MC UtrechtHeidelberglaan 1003584 CX Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- Not specified
- Target Recruitment
- 35
Inclusion Criteria
Adults
Haematological malignancies eligible to allo-SCT
Exclusion Criteria
Relapse of allo-SCT within 6 months after allo-SCT
Bilirubin and/or transaminases > 2.5 x normal value
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of aGVHD at day 100.
- Secondary Outcome Measures
Name Time Method Treatment related mortality (TRM) at day 100<br /><br>Donor engraftment (chimerism > 95%) at day 100<br><br />